Table 3.
N = 46 | Mean (range) | n (%) |
---|---|---|
Cancer diagnosis | ||
Age at first cancer diagnosis (years) | 53.6 (6.3–89.3) | 46 (100) |
Bile duct | 1 (2) | |
Breast | 14 (30) | |
Colon | 1 (2) | |
Hodgkin’s lymphoma | 1 (2) | |
Leukaemia | 3 (7) | |
Lung | 1 (2) | |
Lymphoma | 7 (15) | |
Non-Hodgkin’s | 11 (24) | |
Oesophagus | 1 (2) | |
Osteosarcoma | 4 (9) | |
Prostate | 1 (2) | |
Missing | 1 (2) | |
Agent Class | ||
Chemotherapy cyclesb,c | 5.2 (1–18) | |
Alkylating | Mean dose (mg) | |
Carboplatin | 520.0 | 2 (4) |
Chlorambucila | 1 (2) | |
Cisplatin | 113.3 | 5 (11) |
Cyclophosphamide | 1148.1 | 21 (48) |
Anthracyclines | ||
Doxorubicin | 462.1 | 18 (39) |
Epirubicin | 164.0 | 2 (4) |
Anthracycline combination | ||
ABVDa | 1 (2) | |
Antibiotic cytotoxics | ||
Bleomycin | 20.0 | 1 (2) |
Antimetabolites | ||
ATRA Azacitidine therapy | 100.0 | 1 (2) |
Adjuvant CTx with carboplatin/gemcitabinea | 1 (2) | |
Fluorouracil | 980.0 | 3 (7) |
Methotrexate | 63.0 | 5 (11) |
Fludarabine phosphatea | 1 (2) | |
Mitotic Inhibitors | ||
Amsacrine | 140.0 | 1 (2) |
Docetaxel | 145.7 | 4 (9) |
Etoposide | 200.0 | 1 (2) |
Paclitaxel | 429.0 | 3 (7) |
Vincristinea | 12 (26) | |
Monoclonal Antibodies | ||
Rituximab | 655.0 | 11 (24) |
Trastuzumab | 378.1 | 7 (15) |
Radiation therapy | 28 (61) |
a Dose not recorded
b Each patient’s regimen comprised individualised composites and doses of the above cytotoxic agents
c Other drugs taken include: amiloride, amiodarone, amlodipine, atenolol, atorvastatin, bisoprolol, candesartan, carvedilol, cephalexin, cholecalciferol, clonidine, clopidogrel, digoxin, diltiazem, enalapril, enoxaparin, eprosartan, exemestane, frusemide, ibandronate, irbesartan, itraconazole, ivabradine, letrozole, lisinopril, metoprolol, telmisartan/hydrochlorothiazide, nebivolol, olmesartan, oxycodone, pantoprazole, perindopril, prazosin, prednisolone, ramipril, rivaroxaban, simvastatin, sotalol, spironolactone, tamoxifen, tazocin, goserelin zoledronic acid and vancomycin